Among children with cystic fibrosis (CF), starting the approved oral therapy Orkambi (ivacaftor/lumacaftor) led to favorable changes in…
Articles by Andrea Lobo, PhD
In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers…
Oransi has donated air purifiers to help people with cystic fibrosis (CF) affected by smoke-filled air from the…
Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101,…
People with cystic fibrosis (CF) saw sustained reductions in the use of several other CF therapies after two years…
A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic…
A cystic fibrosis (CF) therapy slightly but significantly increased diversity in the lung microbiome, the community of microorganisms found…
A clinical trial assessing the safety and tolerability of CMTX-101, an antibody-based therapy for cystic fibrosis (CF) lung infections,…
The abundance of Pseudomonas bacteria and related virulence factors in the lungs of people with cystic fibrosis (CF) after…
The 10th Annual Glow Ride for Cystic Fibrosis (CF), held Sept. 21 at Hermosa Beach, California, exceeded expectations by…